To explore potential therapeutic drugs for cardiac hypertrophy and HF, our study screened the effects of FDA-approved chemical compounds library on the transcriptional activity of Myh7 and Bnp based on luciferase reporter assays (Figure 1A). The gene discussed is MYH7; the disease is hydrops fetalis.